Sandoz Miacalcin calcitonin nasal spray approved for second-line treatment of osteoporosis.
SANDOZ MIACALCIN NASAL SPRAY FOR TREATING OSTEOPOROSIS in women who do not want to or cannot take estrogens is approved Aug. 18. According to Sandoz, approximately 30%-50% of postmenopausal women will not or cannot take estrogens. The NDA (20-313) for the salmon calcitonin nasal spray was cleared by FDA after a review period of two years and seven months, having been filed in July 1993.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth